EUVIMEDEUVIMED entdecken
Crossref

Discovery of a Covalent Small-Molecule eEF1A1 Inhibitor via Structure-Based Virtual Screening

Yangping Deng iD, Sizheng Li, Liang Wang, Jianping Lin iD, Haohao Fu iD, Jing Li iD, Yue Chen iD

Journal of Chemical Information and Modeling · 2026

DOI: 10.1021/acs.jcim.5c02496 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Chemical Information and Modeling, 2026. Verfasst von Yangping Deng und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Chemistry, State Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for New Organic Matter, Nankai University, 94 Weij…. Hauptthemen laut MEDLINE: Peptide Elongation Factor 1, Small Molecule Libraries, Drug Discovery. Die Arbeit nennt 69 Literaturangaben. Gefördert von: Ministry of Science and Technology of the People's Republic of China, People's Government of Yunnan Province, Haihe Laboratory of Sustainable Chemical Transformations.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic cancer remains a formidable health challenge due to its late-stage diagnosis and limited therapeutic options, underscoring the need for novel targets and modalities. Our previous work revealed that the natural product, BE-43547A2, could effectively inhibit the progression of pancreatic cancer by the covalent binding to eukaryotic translation elongation factor 1 α 1 (eEF1A1) at Cys234 (C234). Considering the critical role in protein synthesis and the association with pancreatic cancer progression, eEF1A1 is a novel promising target for pancreatic cancer. However, the rational drug design methods for eEF1A1 are extremely lacking. Herein, using microsecond-scale molecular dynamics (MD) simulations, we identify a suitable eEF1A1 conformation for structure-based virtual screening (SBVS) by targeting the residue of C234. Through a tailored SBVS pipeline, we identified AKOS-04 as a novel small-molecule covalent inhibitor with nanomolar-level potency (IC50 = 28.5 ± 2.86 nM in the PATU8988T cell line). Notably, cellular thermal shift assays (CETSA), with the treatments of dithiothreitol (DTT) and iodoacetamide (IAM), confirmed the covalent Cys-involved interaction of AKOS-04 and eEF1A1. Further structural modification validated the critical contribution of a double bond in the acrylamide group of AKOS-04 for its covalent binding with eEF1A1, manifested by the abolished inhibitory activity of compound 9 with the changed single bond in the acrylamide group. MST experiments confirmed direct binding of the compounds to eEF1A1 protein. AKOS-04 exhibited the strongest binding among the tested compounds, consistent with effective covalent target. Finally, MD simulations and pair-interaction energy analyses highlighted Lys84, Arg218, and Glu230 of eEF1A1 as key residues for driving its binding interactions to AKOS-04. These results reveal that AKOS-04, screened by SBVS against C234 of eEF1A1, represents a promising lead for eEF1A1-targeted pancreatic cancer therapy, highlighting the power of computational approaches in covalent drug discovery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peptide Elongation Factor 1Small Molecule LibrariesDrug DiscoveryMolecular Dynamics SimulationHumansCell Line, TumorMolecular Docking SimulationDrug Evaluation, Preclinical

Substanzen

Peptide Elongation Factor 1EEF1A1 protein, humanSmall Molecule Libraries

Autor:innen und Institutionen

  • College of Chemistry, State Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for New Organic Matter, Nankai University, 94 Weijin Road, Tianjin 300071, China.
  • State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, China.
  • Biodesign Center, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, 32 West seventh Avenue, Tianjin Airport Economic Area, Tianjin 300308, China.
  • Research Center for Analytical Sciences, Frontiers Science Center for New Organic Matter,College of Chemistry, Nankai University, Tianjin Key Laboratory of Biosensing and Molecular Recognition, State Key Laboratory of M…
  • Haihe Laboratory of Sustainable Chemical Transformations, Tianjin 300192, China.
  • Haihe Laboratory of Sustainable Chemical Transformations, 6 Keyanxi Road, Tianjin 300192, China.

ORCID-Profile: Yangping Deng, Jianping Lin, Haohao Fu, Jing Li, Yue Chen

Förderung

  • Ministry of Science and Technology of the People's Republic of China
  • People's Government of Yunnan Province
  • Haihe Laboratory of Sustainable Chemical Transformations
  • Guangzhou Laboratory

Zitieren

APA

Deng, Y., Li, S., Wang, L., Lin, J., Fu, H., Li, J., & Chen, Y. (2026). Discovery of a Covalent Small-Molecule eEF1A1 Inhibitor via Structure-Based Virtual Screening. Journal of Chemical Information and Modeling. https://doi.org/10.1021/acs.jcim.5c02496

Vancouver

Deng Y, Li S, Wang L, Lin J, Fu H, Li J, et al. Discovery of a Covalent Small-Molecule eEF1A1 Inhibitor via Structure-Based Virtual Screening. Journal of Chemical Information and Modeling. 2026. doi:10.1021/acs.jcim.5c02496

BibTeX
@article{Deng2026,
  author = {Deng, Yangping and Li, Sizheng and Wang, Liang and Lin, Jianping and Fu, Haohao and Li, Jing and Chen, Yue},
  title = {Discovery of a Covalent Small-Molecule eEF1A1 Inhibitor via Structure-Based Virtual Screening},
  journal = {Journal of Chemical Information and Modeling},
  year = {2026},
  doi = {10.1021/acs.jcim.5c02496}
}
Kostenlos starten →